Hiroaki Muguruma

520 total citations
15 papers, 408 citations indexed

About

Hiroaki Muguruma is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hiroaki Muguruma has authored 15 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hiroaki Muguruma's work include Peptidase Inhibition and Analysis (4 papers), Bone health and treatments (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Hiroaki Muguruma is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Bone health and treatments (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Hiroaki Muguruma collaborates with scholars based in Japan, United Kingdom and United States. Hiroaki Muguruma's co-authors include Saburo Sone, Seiji Yano, Soji Kakiuchi, Hisanori Uehara, Emiko Nakataki, Masaki Hanibuchi, Seiji Yano, Nobutaka Edakuni, Toyokazu Miki and Takanori Kanematsu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and International Journal of Cancer.

In The Last Decade

Hiroaki Muguruma

15 papers receiving 401 citations

Peers

Countries citing papers authored by Hiroaki Muguruma

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Muguruma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Muguruma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Muguruma more than expected).

Fields of papers citing papers by Hiroaki Muguruma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Muguruma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Muguruma. The network helps show where Hiroaki Muguruma may publish in the future.

Co-authorship network of co-authors of Hiroaki Muguruma

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Muguruma. A scholar is included among the top collaborators of Hiroaki Muguruma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Muguruma. Hiroaki Muguruma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A rare etiology of mild encephalitis/encephalopathy with reversible splenial lesion 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), Hiroaki Muguruma, (unknown), (unknown)	3
2	Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice 2009 ·Molecular Cancer Therapeutics ·Tadaaki Yamada, Hiroaki Muguruma, Seiji Yano, Kenji Ikuta, Hirokazu Ogino, Soji Kakiuchi, Masaki Hanibuchi, Hisanori Uehara, Yasuhiko Nishioka, Saburo Sone	14
3	[Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer]. 2008 ·PubMed ·Akiko Abe, Hiroshi Ikawa, Hiroaki Muguruma, Yasuhiro Maeda	4
4	Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell–Depleted SCID Mice 2008 ·Clinical Cancer Research ·Hirokazu Ogino, Seiji Yano, Soji Kakiuchi, Hiroaki Muguruma, Kenji Ikuta, Masaki Hanibuchi, Hisanori Uehara, Kunihiro Tsuchida, Hiromu Sugino, Saburo Sone	65
5	Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions 2007 ·The Journal of Medical Investigation ·(unknown), Seiji Yano, Hiroaki Muguruma, Soji Kakiuchi, Saburo Sone	18
6	Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES‐10 cells) highly expressing vascular endothelial growth factor and its receptor 2006 ·Cancer Science ·Emiko Nakataki, Seiji Yano, (unknown), Hisatsugu Goto, Soji Kakiuchi, Hiroaki Muguruma, Yoshiyuki Bando, Hisanori Uehara, Hironobu Hamada, Katsumi Kito, Akihito Yokoyama, Saburo Sone	40
7	Restored Expression of the MYO18B Gene Suppresses Orthotopic Growth and the Production of Bloody Pleural Effusion by Human Malignant Pleural Mesothelioma Cells in SCID Mice 2006 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Nobutaka Edakuni, Kenji Ikuta, Seiji Yano, Emiko Nakataki, Hiroaki Muguruma, Hisanori Uehara, Masachika Tani, Jun Yokota, Hisamichi Aizawa, Saburo Sone	11
8	Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity 2005 ·Clinical Cancer Research ·Hiroaki Muguruma, Seiji Yano, Soji Kakiuchi, Hisanori Uehara, Makoto Kawatani, Hiroyuki Osada, Saburo Sone	39
9	Src Tyrosine Kinase Inhibitor, M475271, Suppresses Subcutaneous Growth and Production of Lung Metastasis Via Inhibition of Proliferation, Invasion, and Vascularization of Human Lung Adenocarcinoma Cells 2005 ·Clinical & Experimental Metastasis ·Rui Zheng, Seiji Yano, (unknown), Emiko Nakataki, Hiroaki Muguruma, Masanori Yoshizumi, Saburo Sone	18
10	Retreatment of Lung Adenocarcinoma Patients With Gefitinib Who Had Experienced Favorable Results From Their Initial Treatment With This Selective Epidermal Growth Factor Receptor Inhibitor: A Report of Three Cases 2005 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Seiji Yano, Emiko Nakataki, (unknown), Mami Inayama, (unknown), Nobutaka Edakuni, Soji Kakiuchi, (unknown), Hiroaki Muguruma, Saburo Sone	85
11	Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined Immunodeficient Mice 2005 ·Clinical Cancer Research ·Seiji Yano, Hiroaki Muguruma, (unknown), Hisatsugu Goto, Emiko Nakataki, Nobutaka Edakuni, (unknown), Soji Kakiuchi, Akihiko Yamamoto, Hisanori Uehara, Anderson J. Ryan, Saburo Sone	33
12	Parathyroid hormone‐related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC‐5 cells in natural killer cell‐depleted SCID mice 2003 ·International Journal of Cancer ·Toyokazu Miki, Seiji Yano, Masaki Hanibuchi, Takanori Kanematsu, Hiroaki Muguruma, Saburo Sone	49
13	[Non-small cell lung cancer: 1) Molecular-target therapy]. 2003 ·PubMed ·Hiroaki Muguruma, Seiji Yano, Saburo Sone	2
14	A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice 2003 ·Clinical & Experimental Metastasis ·Helong Zhang, Seiji Yano, Toyokazu Miki, Hisatsugu Goto, Takanori Kanematsu, Hiroaki Muguruma, Hisanori Uehara, Saburo Sone	25
15	[Four cases of cancer of unknown primary site that manifested as mediastinal metastatic lesions]. 1999 ·PubMed ·(unknown), (unknown), (unknown), Hiroki Tanaka, Hiroaki Muguruma, Hirokazu Doi, Tomoko Nakayama	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact